A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03227042|
Recruitment Status : Recruiting
First Posted : July 24, 2017
Last Update Posted : November 22, 2017
|Condition or disease|
|Mucopolysaccharidosis Type IIIB|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)|
|Actual Study Start Date :||November 16, 2017|
|Estimated Primary Completion Date :||July 31, 2022|
|Estimated Study Completion Date :||November 15, 2022|
- Neurocognitive function [ Time Frame: Baseline + every 24 weeks for up to 192 weeks ]A neurodevelopmental assessment will be performed using standardized developmental tests to provide quantifiable measures of neurocognitive function.
- Behavioral function [ Time Frame: Baseline + every 24 weeks for up to 192 weeks ]Disease-related behaviors will be assessed using an MPS IIIB specific behavior rating scale.
- Quality of Life Tests [ Time Frame: Baseline + every 24 weeks for up to 192 weeks ]Multiple QoL tools will be used to capture physical, mental, and social well-being of the patient as well as to examine the impact of the patient's disease on the parent/guardian and family.
- Sleep habits [ Time Frame: Baseline + every 24 weeks for up to 192 weeks ]Patient sleep habits will be assessed using Children's Sleep Habits Questionnaires (CSHQ).
- Disease-specific Biomarkers [ Time Frame: Baseline + every 24 weeks for up to 192 weeks ]Urine sample for glycosaminoglycans (GAGs) and creatinine.
- Biochemical, Molecular, Cellular and Genetic Markers of Disease Burden [ Time Frame: Once (at baseline visit) ]Blood and urine samples will be used to evaluate biochemical, molecular cellular, and genetic/genomic aspects of MPS IIIB.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03227042
|Contact: BioMarin Trial Inquiriesemail@example.com|
|United States, California|
|UCSF Benioff Children's Hospital Oakland||Not yet recruiting|
|Oakland, California, United States, 94609|
|Contact: Christopher Luc 510-428-3885 ext 4785 firstname.lastname@example.org|
|Principal Investigator: Paul Harmatz, MD|
|Murdoch Childrens Research Institute and Royal Children's Hospital||Recruiting|
|Melbourne, Victoria, Australia, 3052|
|Contact: Shannon Kokoszka +61 3 9936 6157 email@example.com|
|Principal Investigator: Heidi Peters, MD|
|Medical Genetics Service/HCPA, Department of Genetics/UFRGS||Not yet recruiting|
|Pôrto Alegre, Rio Grande Do Sul, Brazil, 90035-903|
|Contact: Larissa Da Silva +55 51 3359 6366 firstname.lastname@example.org|
|Principal Investigator: Roberto Giugliani, MD|
|University Medical Center Hamburg-Eppendorf||Recruiting|
|Hamburg, Germany, 20246|
|Contact: Martina Lippold 49-40-7410-53710 email@example.com|
|Contact: Julia Voelker 00 firstname.lastname@example.org|
|Principal Investigator: Nicole Muschol, MD|
|Hospital Clínico Universitario de Santiago||Recruiting|
|Santiago de Compostela, A Coruña, Spain, 15706|
|Contact: María José De Castro +34.6126.96.36.199 email@example.com|
|Principal Investigator: Maria Luz Couce, MD|
|MacKay Memorial Children's Hospital||Recruiting|
|Taipei, Taiwan, 10449|
|Contact: Youhsin Huang +886-2-25433535 ext 3089 firstname.lastname@example.org|
|Principal Investigator: Shuan-Pei Lin, MD|
|Gazi University Faculty of Medicine||Recruiting|
|Ankara, Turkey, 06560|
|Contact: Mine Tutkal +90 505 253 86 34 email@example.com|
|Principal Investigator: Ilyas Okur, MD|
|Study Director:||Medical Director, MD||BioMarin Medical Monitor|